- Home
- DMA vs DTIL Comparison
DMA vs DTIL Comparison
Compare DMA & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMA
- DTIL
- Stock Information
- Founded
- DMA 2011
- DTIL 2006
- Country
- DMA United States
- DTIL United States
- Employees
- DMA N/A
- DTIL N/A
- Industry
- DMA Trusts Except Educational Religious and Charitable
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- DMA Finance
- DTIL Health Care
- Exchange
- DMA Nasdaq
- DTIL Nasdaq
- Market Cap
- DMA 79.1M
- DTIL 81.4M
- IPO Year
- DMA N/A
- DTIL 2019
- Fundamental
- Price
- DMA $8.67
- DTIL $5.25
- Analyst Decision
- DMA
- DTIL Strong Buy
- Analyst Count
- DMA 0
- DTIL 2
- Target Price
- DMA N/A
- DTIL $47.00
- AVG Volume (30 Days)
- DMA 34.6K
- DTIL 245.6K
- Earning Date
- DMA 01-01-0001
- DTIL 11-03-2025
- Dividend Yield
- DMA 2.04%
- DTIL N/A
- EPS Growth
- DMA N/A
- DTIL N/A
- EPS
- DMA N/A
- DTIL N/A
- Revenue
- DMA N/A
- DTIL $698,000.00
- Revenue This Year
- DMA N/A
- DTIL N/A
- Revenue Next Year
- DMA N/A
- DTIL $135.19
- P/E Ratio
- DMA N/A
- DTIL N/A
- Revenue Growth
- DMA N/A
- DTIL N/A
- 52 Week Low
- DMA $4.78
- DTIL $3.61
- 52 Week High
- DMA $8.00
- DTIL $8.82
- Technical
- Relative Strength Index (RSI)
- DMA 43.98
- DTIL 33.72
- Support Level
- DMA $8.56
- DTIL $5.67
- Resistance Level
- DMA $8.88
- DTIL $6.46
- Average True Range (ATR)
- DMA 0.07
- DTIL 0.59
- MACD
- DMA 0.00
- DTIL -0.27
- Stochastic Oscillator
- DMA 26.00
- DTIL 4.04
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.